+44 (0)1865 595230
0 Items

West Nile Virus

West Nile Virus (WNV) is a cause of neurological disease and death in humans. WNV reached North America in 1999, resulting in a large and dramatic outbreak that continued to spread throughout the USA in the following years. The US WNV outbreak (1999-2010) highlighted the risk posed by importation of vector-borne pathogens outside of their normal range. Since, the virus has spread and is now widely established from Canada to Venezuela.

The Native Antigen Company offers a range of recombinant WNV antigens and highly specific monoclonal antibodies to support research into the infection and assay development.

West Nile Virus Background

West Nile Virus (WNV) is an enveloped, single-stranded RNA virus that belongs to the Flavivirus genus. WNV is a member of the Japanese encephalitis sero-complex, of the family Flaviviridae, which also includes Japanese encephalitis virus, St. Louis encephalitis and Murray Valley encephalitis virus. In nature, West Nile virus is maintained in a cycle between birds and mosquitoes. However, WNV can also be transmitted to incidental hosts such as humans, horses and other mammals by mosquito vectors.

Since the first human WNV infection was identified in 1937, the virus has continued to spread. West Nile virus is now found in many regions of the world including Africa, Europe, West Asia, North and South America. WNV infection is asymptomatic in 80% of cases, but some individuals can develop severe West Nile fever. The symptoms of West Nile fever include fever, headache, nausea and vomiting. The virus has also been associated with neurological complications and fatalities in less than 1% of infected individuals.

Currently, there is no licensed prophylactic vaccine or specific therapeutic treatment for West Nile virus infection in humans. Prevention of WNV infection is through vector control measures and the use of protective clothing to reduce human-to-human transmission.

Reference

  1. Chancey C, et al (2015). The Global Ecology and Epidemiology of West Nile Virus. Biomed Res Int. 376230.

West Nile Virus Antigens

The Native Antigen Company specialises in development and manufacture of native and recombinant viral antigens. Our recombinant antigens are used by pharmaceutical and IVD manufacturers in vaccine research and serology, where proper folding and glycosylation are vital.

We prepare West Nile virus NS1 protein in our proprietary mammalian cell expression system, which generates highly pure NS1 protein in its glycosylated and predominantly hexameric form. Our West Nile virus antigen is ideal for use in immunoassay development and vaccine R&D.

West Nile Virus Antibodies

We have used our recombinant WNV NS1 protein to raise a panel of specific antibodies to WNV NS1 protein, all of which are highly specific and do not cross-react with NS1 proteins from other flaviviruses, including Dengue, Yellow Fever and Japanese Encephalitis viruses

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

12 + 3 =

Live Customer Feedback